Literature DB >> 12928646

Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.

Gabriel Thabut1, Hervé Mal, Yves Castier, Odile Groussard, Olivier Brugière, Rolana Marrash-Chahla, Guy Lesèche, Michel Fournier.   

Abstract

OBJECTIVE: Although lung transplantation is viewed as an acceptable option for patients with end-stage idiopathic pulmonary fibrosis, the survival benefit of this approach is still debated. This study examined whether there was a survival benefit of lung transplantation in a cohort of patients referred to our transplant center with a diagnosis of idiopathic pulmonary fibrosis according to American Thoracic Society criteria.
METHODS: Forty-six patients accepted for lung transplantation during a 12-year period with a diagnosis of idiopathic pulmonary fibrosis form the basis of this study. Survival benefit offered by lung transplantation was assessed using Cox proportional-hazards modeling, with patients on a waiting list as the control group.
RESULTS: Twenty-eight patients underwent lung transplantation (27 single and 1 double), 16 patients died while waiting, and 2 patients remained on the active waiting list. Diagnosis of idiopathic pulmonary fibrosis was made on histologic examination of the explanted lung or lung biopsy before lung transplantation. There was a pattern of usual interstitial pneumonia in 31 cases (67%). The 15 remaining patients fulfilled all American Thoracic Society criteria for idiopathic pulmonary fibrosis. The median waiting time for organs was 51 days. Survival after lung transplantation was 79.4% at 1 year, 63.5% at 2 years, and 39% at 5 years. The multivariable analysis showed that lung transplantation reduced the risk of death by 75% (95% confidence interval, 8%-86%; P =.03) after adjustment on potential confounding variables.
CONCLUSIONS: Lung transplantation is effective in improving the survival of selected patients affected by idiopathic pulmonary fibrosis.

Entities:  

Mesh:

Year:  2003        PMID: 12928646     DOI: 10.1016/s0022-5223(03)00600-7

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  48 in total

1.  Remodeling of mechanical junctions and of microtubule-associated proteins accompany cardiac connexin43 lateralization.

Authors:  Halina S Chkourko; Guadalupe Guerrero-Serna; Xianming Lin; Nedal Darwish; Joshua R Pohlmann; Keith E Cook; Jeffrey R Martens; Eli Rothenberg; Hassan Musa; Mario Delmar
Journal:  Heart Rhythm       Date:  2012-03-07       Impact factor: 6.343

2.  Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation.

Authors:  Nilto C De Oliveira; Satoru Osaki; James Maloney; Richard D Cornwell; Keith C Meyer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-16

Review 3.  [Idiopathic interstitial pneumonias: from classification to diagnostic work-up].

Authors:  C Müller-Mang; L Stiebellehner; K Schmid; A Bankier
Journal:  Radiologe       Date:  2007-05       Impact factor: 0.635

4.  Assessing the causal effect of organ transplantation on the distribution of residual lifetime.

Authors:  David M Vock; Anastasios A Tsiatis; Marie Davidian; Eric B Laber; Wayne M Tsuang; C Ashley Finlen Copeland; Scott M Palmer
Journal:  Biometrics       Date:  2013-10-15       Impact factor: 2.571

5.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

6.  Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis.

Authors:  L Ten Klooster; C H M van Moorsel; J M Kwakkel-van Erp; H van Velzen-Blad; J C Grutters
Journal:  Clin Exp Immunol       Date:  2015-06-08       Impact factor: 4.330

7.  Lung transplant in end-staged chronic obstructive pulmonary disease (COPD) patients: a concise review.

Authors:  Fahad Aziz; Sudheer Penupolu; Xin Xu; Jianxing He
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

Review 8.  Transplant options for end stage chronic obstructive pulmonary disease in the context of multidisciplinary treatments.

Authors:  Luigi Santambrogio; Paolo Tarsia; Paolo Mendogni; Davide Tosi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

9.  Advances in the management of idiopathic pulmonary fibrosis.

Authors:  Jay H Ryu; Craig E Daniels
Journal:  F1000 Med Rep       Date:  2010-04-12

10.  Spirometric assessment of lung transplant patients: one year follow-up.

Authors:  Paulo M Pêgo-Fernandes; Fernando Conrado Abrão; Frederico Leon Arrabal Fernandes; Marlova L Caramori; Marcos Naoyuki Samano; Fabio B Jatene
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.